Codegate는 AI 에이전트 시스템을 위한 오픈 소스 보안 게이트웨이 및 멀티플렉싱 프레임워크입니다. Stacklok이 개발했으며, 안전한 작업 공간과 정책 기반 접근 제어를 제공하여 개발자가 복잡한 다중 에이전트 애플리케이션을 안전하고 효율적으로 구축하고 관리할 수 있도록 지원합니다.
DrugCard는 약물 감시를 위해 설계된 AI 기반 데이터 인텔리전스 플랫폼입니다. 현지 의료 문헌 스크리닝 프로세스를 자동화하여 제약 회사, CRO 및 프리랜서가 여러 언어와 지역에 걸쳐 약물 안전 및 규제 준수를 효율적으로 보장하도록 돕습니다.
제품 개요
codegate 제품 개요
Codegate는 AI 에이전트 시스템을 위한 오픈 소스 보안 게이트웨이 및 멀티플렉싱 프레임워크입니다. Stacklok이 개발했으며, 안전한 작업 공간과 정책 기반 접근 제어를 제공하여 개발자가 복잡한 다중 에이전트 애플리케이션을 안전하고 효율적으로 구축하고 관리할 수 있도록 지원합니다.
DrugCard 제품 개요
DrugCard는 약물 감시를 위해 설계된 AI 기반 데이터 인텔리전스 플랫폼입니다. 현지 의료 문헌 스크리닝 프로세스를 자동화하여 제약 회사, CRO 및 프리랜서가 여러 언어와 지역에 걸쳐 약물 안전 및 규제 준수를 효율적으로 보장하도록 돕습니다.
Detailed feature comparison
| Feature | codegate | DrugCard |
|---|---|---|
| 주요 카테고리 | 주체적 프레임워크 | 약물감시 |
| 등록일 | 2025-08-16 | 2025-08-10 |
| 가격 | 무료 | 유료 |
| 공식 사이트 | github.com | drug-card.io |
| 제품 유형 | 앱 | 웹사이트 |
| Performance data | ||
| 사용자 평점 | 확인되지 않음 | 확인되지 않음 |
| 댓글 | 0 | 0 |
| 월 방문 | 636.1M | 5.6K |
| 월 성장률 | 0.8% | 51.1% |
| 즐겨찾기 | 108 | 132 |
| Details | 상세 보기 | 상세 보기 |
codegate vs DrugCard monthly traffic
Compare codegate and DrugCard by monthly reach, traffic trend, visit depth, top regions, and acquisition sources.
How to interpret the traffic data
In the codegate vs DrugCard monthly traffic comparison, codegate currently shows 636.1M visits and DrugCard shows 5.6K; codegate has about 113,971.7 times the visible traffic of DrugCard, an absolute difference of about 636.1M visits. This reflects visible reach, not feature quality or paid users.
Both tools provide verified traffic details, so monthly trends, visit depth, regions, and acquisition sources can be compared on the same basis.
codegate is registered at the github.com/stacklok subpage. Because the current data does not state whether other host pages are excluded, treat this as domain-level context rather than independent traffic for one product or project.
codegate monthly traffic:
Latest traffic
Monthly traffic trend
- 2026/1: 542.6M 월 방문
- 2026/2: 534.8M 월 방문
- 2026/3: 634.3M 월 방문
- 2026/4: 631M 월 방문
- 2026/5: 636.1M 월 방문
주요 지역
Top 5 countries/regions
| Country/region | Percentage | Traffic |
|---|---|---|
| 🇺🇸United States | 36.14% | 229.9M |
| 🇨🇳China | 22.96% | 146M |
| 🇮🇳India | 17.41% | 110.7M |
| 🇷🇺Russia | 15.84% | 100.8M |
| 🇩🇪Germany | 7.65% | 48.7M |
트래픽 소스
| Source type | Percentage | Traffic |
|---|---|---|
| 직접 | 82.14% | 522.5M |
| 리퍼럴 | 16.14% | 102.7M |
| 이메일 | 1.72% | 10.9M |
검색 키워드
DrugCard monthly traffic:
Latest traffic
Monthly traffic trend
- 2025/9: 6.8K 월 방문
- 2026/1: 4.1K 월 방문
- 2026/2: 5.5K 월 방문
- 2026/3: 5.2K 월 방문
- 2026/4: 3.7K 월 방문
- 2026/5: 5.6K 월 방문
주요 지역
Top 5 countries/regions
| Country/region | Percentage | Traffic |
|---|---|---|
| 🇺🇸United States | 69.05% | 3.9K |
| 🇮🇳India | 17.3% | 966 |
| 🇭🇺Hungary | 8.29% | 463 |
| 🇵🇱Poland | 3.6% | 201 |
| 🇮🇪Ireland | 1.76% | 98 |
검색 키워드
Usage comparison
Compare the core capabilities of codegate and DrugCard
codegate Core features
DrugCard Core features
Use cases
codegate Use cases
DrugCard Use cases
codegate vs DrugCard:In-depth comparison and selection guidance
First decide whether the products solve the same kind of need
This in-depth codegate vs DrugCard comparison uses only the product records, taxonomy, audience, traffic, and community signals available on this page. codegate is primarily listed under “주체적 프레임워크”, while DrugCard is primarily listed under “약물감시”, so the first decision is whether your actual task matches their recorded scope.
The structured fields currently show these decision-relevant differences: Primary category (codegate: 주체적 프레임워크; DrugCard: 약물감시); Product type (codegate: App; DrugCard: Website); Pricing (codegate: Free; DrugCard: Paid); Monthly visits (codegate: 636.1M; DrugCard: 5.6K); Monthly growth (codegate: 0.8%; DrugCard: 51.1%). These facts are more useful for selection than brand visibility alone.
What market visibility and monthly traffic mean
In the codegate vs DrugCard monthly traffic comparison, codegate currently shows 636.1M visits and DrugCard shows 5.6K; codegate has about 113,971.7 times the visible traffic of DrugCard, an absolute difference of about 636.1M visits. This reflects visible reach, not feature quality or paid users.
Both tools provide verified traffic details, so monthly trends, visit depth, regions, and acquisition sources can be compared on the same basis.
codegate is registered at the github.com/stacklok subpage. Because the current data does not state whether other host pages are excluded, treat this as domain-level context rather than independent traffic for one product or project.
codegate is registered under a github.com subpath, so its large visible total may include the host platform. The current data does not justify choosing codegate for traffic alone; shortlist by unique taxonomy and use case, then validate with the same tasks.
Product positioning, use cases, and roles
codegate and DrugCard currently overlap in shared categories: 자동화; shared tags: 자동화. This can place both on the same shortlist, but it does not prove equal implementation, depth, or cost.
codegate's unique categories/tags are 주체적 프레임워크, 보안, AI 에이전트, AI 보안, 개발자 도구, DevSecOps, 쿠버네티스 및 오픈 소스; DrugCard's are 약물감시, 제약 AI, CRO 도구, 데이터 인텔리전스, 약물 안전, 의료 AI, 의학 문헌 스크리닝 및 규제 준수. These unique fields are the strongest differentiators: validate the product whose recorded scope matches the task instead of following traffic alone.
What ratings, comments, and favorites can tell you
codegate has no verified rating, 0 comments, 108 favorites, and 111 likes;DrugCard has no verified rating, 0 comments, 132 favorites, and 138 likes。
Neither product has enough rating or comment samples for a credible reputation ranking.
Selection guidance by actual need
When to evaluate codegate first
Put codegate on the priority trial list when the task aligns with “주체적 프레임워크” and especially 주체적 프레임워크, 보안, AI 에이전트, AI 보안, 개발자 도구 및 DevSecOps. This follows recorded positioning and does not imply unlisted capabilities are absent.
codegate also currently records: pricing is free, product type is app, 636.1M monthly visits shown for the registered host (subpage scope unknown), no verified user rating. Verify any hard requirement around price, platform, or reach before trial, and do not let sparse review data substitute for testing.
When to evaluate DrugCard first
Put DrugCard on the priority trial list when the task aligns with “약물감시” and especially 약물감시, 제약 AI, CRO 도구, 데이터 인텔리전스, 약물 안전 및 의료 AI. This follows recorded positioning and does not imply unlisted capabilities are absent.
DrugCard also currently records: pricing is paid, product type is website, 5.6K verified monthly visits, no verified user rating. Verify any hard requirement around price, platform, or reach before trial, and do not let sparse review data substitute for testing.
How to validate the recommendation before deciding
The available data describes positioning, public visibility, and community signals, but it cannot prove output quality, speed, integration effort, privacy, or long-term cost in your workflow. Before deciding, run the same representative tasks in codegate and DrugCard, then record completion time, accuracy, manual corrections, and the real paid threshold. A like-for-like trial turns this comparison into a defensible adoption decision.




